Oncotarget

Reviews:

p53, p63 and p73 in the wonderland of S. cerevisiae

Olivier Billant, Marc Blondel and Cécile Voisset _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:57855-57869. https://doi.org/10.18632/oncotarget.18506

Metrics: PDF 2110 views  |   HTML 3031 views  |   ?  


Abstract

Olivier Billant1, Marc Blondel1,* and Cécile Voisset1,*

1Inserm UMR 1078, Université de Bretagne Occidentale, Faculté de Médecine et des Sciences de la Santé, Etablissement Français du Sang (EFS) Bretagne, CHRU Brest, Hôpital Morvan, Laboratoire de Génétique Moléculaire, Brest, France

*These authors have contributed equally to this work

Correspondence to:

Cécile Voisset, email: [email protected]

Marc Blondel, email: [email protected]

Keywords: p53, p63, p73, yeast, FASAY

Received: March 31, 2017    Accepted: April 26, 2017    Published: June 16, 2017

ABSTRACT

Since its discovery in 1979, p53 has been on the forefront of cancer research. It is considered a master gene of cancer suppression and is found mutated in around 50% of all human tumors. In addition, the progressive identification of p53-related transcription factors p63 and p73 as well as their multiple isoforms have added further layers of complexity to an already dense network. Among the numerous models used to unravel the p53 family mysteries, S. cerevisiae has been particularly useful. This seemingly naive model allows the expression of a functional human p53 and thus the assessment of p53 intrinsic transcriptional activity. The aim of this article is to review the various contributions that the budding yeast has made to the understanding of p53, p63 and p73 biology and to envision new possible directions for yeast-based assays in the field of cancer as well as other p53-family-related diseases.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18506